C-reactive protein, inflammation, and coronary risk.
Data have revealed interactions between baseline concentration of hs-CRP and the efficacy of common pharmacologic therapies in primary and secondary prevention, suggesting not only that it may be possible to modify the increased risk associated with elevated hs-CRP, but also that inflammatory markers may be useful in targeting preventive therapies. Inflammatory markers may become a valuable component of routine cardiovascular risk assessment.
Morrow
D A
DA
Division of Cardiovascular Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Ridker
P M
PM
D002097:C-Reactive Protein / Q000378:metabolism*; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D007249:Inflammation / Q000150:complications* / Q000175:diagnosis; D018836:Inflammation Mediators / Q000097:blood; D009203:Myocardial Infarction / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control; D012008:Recurrence; D012307:Risk Factors; D012680:Sensitivity and Specificity
D018836:Inflammation Mediators; D002097:C-Reactive Protein